CD BioGlyco is pleased to provide a cutting-edge glyconanoparticle preclinical research service to a wide range of nano researchers. We are always committed to technological innovation to continuously improve the quality of our services and research capabilities. This innovative capability keeps us at the forefront of the nano field and helps our clients stay ahead of the fierce competition in glyconanoparticle research and realize breakthroughs and translations of their research results.
Get a Quote NowGlyconanoparticles are engineered nanostructures containing carbohydrate molecules that are valuable in biomedical, cosmetic, and agricultural applications. Preclinical research on glyconanoparticles is a critical step in advancing it as it should be. As a leader in the nano field, CD BioGlyco has constructed a very well-established GlycoNano™ Platform and provides a one-stop preclinical research service for glyconanoparticles. Our rich experience in glyconanoparticle R&D ensures that we provide customized solutions and reliable support for glyconanoparticle applied research.
We offer a comprehensive preclinical characterization of glyconanoparticles, which includes elaborate design, synthesis, physicochemical characterization as well as stability testing, in vitro and in vivo pharmacodynamic and pharmacological studies, and bioanalytical and safety pharmacology assessments of glyconanoparticles.
We design the structure and composition of glyconanoparticles according to the target application (e.g. drug delivery, bioimaging, active factor delivery, etc.). This process selects suitable nanoparticle core materials and glycan molecules and determines their binding modes and ratios. Various methods are then used to prepare glyconanoparticles and characterize them in detail. The whole process is carried out according to strict quality standards to ensure the high quality and performance of glyconanoparticles.
We are also very good at developing Glycol Nanohydrogel and provide a one-stop glycol nanohydrogel preclinical study service. Synthesizable glycol nanohydrogel includes the following:
| Types | Glycol Nanohydrogel |
|---|---|
| Natural Polymer-based Glycol Nanohydrogel |
|
| Synthetic Polymer-based Glycol Nanohydrogel |
|
We utilize a variety of advanced scientific techniques and analytical methods to comprehensively and thoroughly characterize the key physicochemical properties and interactions of glyconanoparticles, such as particle size, morphology, surface properties, chemical composition, bioactivity, and stability. By revealing the inherent properties and potential applications of glyconanoparticles, we provide scientific basis and data support for their applications in drug delivery, bio-imaging, and other fields.
| Types | Characterization |
|---|---|
| Physicochemical Property Characterization |
|
| Glyconanoparticle Molecule Interaction Analysis |
|
This process involves studying the bioactivity, targeting, drug release properties, and functionality of glyconanoparticles through in vitro cellular assays and animal models. The entire glyconanoparticle preclinical study process follows strict specifications to ensure the scientific validity and reliability of the study.
In Vitro Models for Glyconanoparticle Delivery Evaluation Service
We have a wealth of in vitro models for detailed evaluation of glyconanoparticle delivery. Detailed services include, but are not limited to, cell culture, determination of glyconanoparticle uptake efficiency in different cell types, study of its intracellular transport mechanism, assessment of its impact on cell function, and prediction of its potential biological effects.
| HeLa cells | iPSCs | 3T3-L1 cells | RAW 264.7 cells | CHO cells | U87MG cells |
| MCF-7 cells | HMSCs | THP-1 cells | L929 cells | DC2.4 cells | Calu-3 cells |
| A549 cells | HEK293 cells | HCT-116 cells | PC3 cells | SH-SY5Y cells | COS-7 cells |
| H460 cells | NRK-52E cells | HepG2 cells | PC12 cells | SKOV3 cells | HaCaT cells |
| MDA-MB-231 cells | HUVECs | Caco-2 cells | MDCK cells | MC3T3-E1 cells | BEAS-2B cells |
In Vivo Models for Glyconanoparticle Delivery Evaluation Service
We have a wealth of in vivo animal models to evaluate the delivery efficiency, biodistribution, tissue uptake, metabolic pathways, and potential biological effects of glyconanoparticles in organisms. In this service, we construct appropriate animal models (e.g., mice, rats, rabbits, etc.) to simulate the mode of administration and dosage of glyconanoparticle in real applications and monitor and track its dynamics in organisms in real time.
By studying the key parameters such as tissue distribution, bioavailability, pharmacological effects on organisms, toxicity, etc., we provide an important experimental basis for the application of glyconanoparticles in drug delivery and other fields.
| By methods | By taxonomy |
|---|---|
|
|
Based on a wealth of in vivo and in vitro models, we offer a comprehensive range of glyconanoparticle preclinical research services including the following.
We study the stability of glyconanoparticles under different environmental conditions (e.g. temperature, humidity, light, pH, ionic strength, etc.). Through a series of scientific and rigorous experimental designs and methodology, we systematically study the physical stability (e.g. particle size change, aggregation state, settling speed, etc.), chemical stability (e.g. surface chemistry, functional group change, degradation, etc.), and storage stability of glyconanoparticles. Through detailed glyconanoparticle stability studies, we ensure the effectiveness and safety of the developed glyconanoparticles in practical applications.
CD BioGlyco provides a professional glyconanoparticle biological characterization service. We utilize a variety of biotechnology and analytical methods to comprehensively and in-depth characterize the biological properties of glyconanoparticles. By studying key biological properties such as interaction with biomolecules, cytotoxicity, cellular uptake, transport mechanisms, and immune response, we provide important basic data and theoretical support for various applications and promote the innovation and development of glycan nanotechnology.
We provide a comprehensive glyconanoparticle pharmacodynamic study service for a detailed evaluation of the biological effects and mechanisms of action of glyconanoparticles. The service specifically includes a variety of experimental approaches to evaluate how these customized glyconanoparticles affect cellular responses, immunomodulation, and the efficiency of targeted drug delivery. By elucidating the pharmacodynamic profile of glyconanoparticles and studying the dose-response relationship, mechanism of action, wound healing, etc., the study will provide information to optimize the design of glyconanoparticles and improve their effectiveness in treating diseases such as cancer.
This service service includes the evaluation of absorption, distribution, metabolism, excretion, and half-life of glyconanoparticles. We design detailed in vitro and in vivo studies to track the behavior of these nanoparticles in biological systems using advanced technologies such as high-performance liquid chromatography and imaging methods to assess their pharmacokinetic profile. The detailed studies provide insights into parameters such as their bioavailability, clearance, tissue distribution, and interactions with biological components, and facilitate the development of more effective targeted therapeutic strategies.
We evaluate in detail the potential toxicity and safety of glyconanoparticles in organisms and their effects on biological systems. The toxic response and adverse effects of glyconanoparticle on organisms (cardiovascular, nervous system, etc.) at different doses and exposure times are systematically studying. Our goal is to provide a scientific basis and risk assessment for the safe application of glyconanoparticle in the fields of disease therapy, active factor delivery, imaging, etc. to ensure its safety and efficacy.
CD BioGlyco is committed to innovation research and development and provides ongoing technical and service support for client glyconanoparticle research.
Technology: Fluorescence-activated cell sorting (FACS)
Journal: Cancers
IF: 5.2
Published: 2022
Results: In this study, a novel nanovaccine (GNP-LLO91-99) was prepared using gold nanoparticles and the bacterial peptide 91–99 of the listeriolysin O toxin for the treatment of bladder cancer. A detailed preclinical study showed that the Listeria nanovaccine stimulated an immune response, activated the immune system, reduced tumor size, and blocked the tumor's immunosuppressive environment. It is used in immunotherapy and has good potential for use in therapeutic studies for melanoma, non-small cell lung cancer, and uroepithelial bladder cancer.
Fig.1 Preparation and analysis of GNP-LLO91-99. (Terán-Navarro, et al., 2022)
CD BioGlyco conducts preclinical studies on glyconanoparticles through a series of rigorous experimental designs and analytical methods, contributing to the advancement of innovation and development of glycan nanotechnology. Please feel free to contact us for further information about our glyconanoparticle preclinical research services.
Reference
